Find in Library

Metabolic syndrome (MetS) significantly predisposes individuals to diabetes and is a prognostic factor for the progression of diabetic nephropathy (DN). This study aimed to evaluate the efficacy of (-)–gallocatechin gallate (GCG) in alleviating signs of MetS-associated DN in <i>db/db</i> mice. We administered GCG and monitored its effects on several metabolic parameters, including food and water intake, urinary output, blood glucose levels, glucose and insulin homeostasis, lipid profiles, blood pressure, and renal function biomarkers. The main findings indicated that GCG intervention led to marked improvements in these metabolic indicators and renal function, signifying its potential in managing MetS and DN. Furthermore, transcriptome analysis revealed substantial modifications in gene expression, notably the downregulation of pro-inflammatory genes such as <i>S100a8</i>, <i>S100a9</i>, <i>Cd44</i>, <i>Socs3</i>, <i>Mmp3</i>, <i>Mmp9</i>, <i>Nlrp3</i>, <i>IL</i>–<i>1β</i>, <i>Osm</i>, <i>Ptgs2</i>, and <i>Lcn2</i> and the upregulation of the anti-oxidative gene <i>Gstm3</i>. These genetic alterations suggest significant effects on pathways related to inflammation and oxidative stress. In conclusion, GCG demonstrates therapeutic efficacy for MetS–associated DN, mitigating metabolic disturbances and enhancing renal health by modulating inflammatory and oxidative responses.